AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2051364 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed Partial Dentures (FPDs)
Number of subjects: 232
Study 2051364 — intervention group
Group type: COMPARATOR
Intervention: Baseline performance scores
Number of subjects: 232
Study 2051364 — intervention group
Group type: COMPARATOR
Intervention: Post-treatment performance scores at 60 months
Number of subjects: 232
Study 6343091 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole (1.3 g/m2, administered 4 hr before the first 9 irradiations)
Number of subjects: 163
Study 6343091 — intervention group
Group type: COMPARATOR
Intervention: Control (no misonidazole)
Number of subjects: 163
Study 31355956 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole + Anidulafungin (combination therapy)
Number of subjects: 454
Study 31355956 — intervention group
Group type: COMPARATOR
Intervention: Voriconazole + Placebo (monotherapy)
Number of subjects: 454
Study 27664999 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 139
Study 27664999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 25944414 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine-tramadol combination (1.3 mL of 2% mepivacaine with epinephrine 1:100,000 plus 0.5 mL of tramadol 50 mg/mL)
Number of subjects: 56
Study 25944414 — intervention group
Group type: COMPARATOR
Intervention: Mepivacaine alone (1.8 mL of 2% mepivacaine with epinephrine 1:100,000)
Number of subjects: 56
Study 25944414 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine-tramadol combination
Number of subjects: 56
Study 25944414 — intervention group
Group type: COMPARATOR
Intervention: Mepivacaine alone
Number of subjects: 56
Study 24365175 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-incision lenticule extraction (SMILE)
Number of subjects: 922
Study 23038043 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg eszopiclone
Number of subjects: 20
Study 23038043 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg eszopiclone
Number of subjects: 20
Study 23038043 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg eszopiclone
Number of subjects: 20
Study 23038043 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg eszopiclone (multiple-dose)
Number of subjects: 20
Study 23038043 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 20
Study 19258640 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpation + fluoroscopy
Number of subjects: 208
Study 19258640 — intervention group
Group type: COMPARATOR
Intervention: Palpation
Number of subjects: 208
Study 17884604 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter intervention advising to reduce or stop benzodiazepine use
Number of subjects: 1256
Study 17884604 — intervention group
Group type: COMPARATOR
Intervention: Control group (no letter intervention)
Number of subjects: 1256
Study 15657462 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 18
Study 15657462 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 18
Study 15657462 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin (in humans)
Number of subjects: 18
Study 12127923 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended dalteparin treatment (5000 or 7500 IU.12h(‐1) to day 90)
Number of subjects: 1601
Study 12127923 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended dalteparin treatment
Number of subjects: 1601
Study 12127923 — intervention group
Group type: COMPARATOR
Intervention: Acute treatment with dalteparin (120 IU/kg(‐1) 12h(‐1) for 5-7 days)
Number of subjects: 1601
Study 10190643 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-directed diabetes prevention and control intervention
Number of subjects: 295
Study 10190643 — intervention group
Group type: COMPARATOR
Intervention: Comparison communities (control)
Number of subjects: 295
Study 7594324 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg daily for 8 weeks (gastric ulcers) or 6 weeks (duodenal ulcers)
Number of subjects: 133
Study 7594324 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg daily for 8 weeks (gastric ulcers) or 6 weeks (duodenal ulcers) plus amoxicillin 2 g daily for 2 weeks
Number of subjects: 133
Study 2041279 — intervention group
Group type: COMPARATOR
Intervention: Captopril (C) 50 mg
Number of subjects: 12
Study 2041279 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ID) 10 mg
Number of subjects: 12
Study 2041279 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (N) 20 mg
Number of subjects: 12
Study 7226712 — intervention group
Group type: EXPERIMENTAL
Intervention: (-)E (enantiomer)
Number of subjects: 0
Study 7226712 — intervention group
Group type: EXPERIMENTAL
Intervention: (-)MET (metabolite)
Number of subjects: 0
Study 7226712 — intervention group
Group type: EXPERIMENTAL
Intervention: +E (enantiomer)
Number of subjects: 0
Study 7226712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7226712 — intervention group
Group type: COMPARATOR
Intervention: Positive controls
Number of subjects: 0
Study 30716450 — intervention group
Group type: EXPERIMENTAL
Intervention: High CES
Number of subjects: 60
Study 30716450 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CES
Number of subjects: 60
Study 30716450 — intervention group
Group type: COMPARATOR
Intervention: Placebo CES
Number of subjects: 60
Study 28952690 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT with concomitant use of tamsulosin
Number of subjects: 50
Study 28952690 — intervention group
Group type: COMPARATOR
Intervention: ADT alone
Number of subjects: 50
Study 27637296 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmonetary incentive (offered a book upon survey completion)
Number of subjects: 3966
Study 27637296 — intervention group
Group type: COMPARATOR
Intervention: No incentive (did not mention the book)
Number of subjects: 3966
Study 27637296 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper mail reminder (letter)
Number of subjects: 3966
Study 27637296 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper mail reminder (postcard)
Number of subjects: 3966
Study 27637296 — intervention group
Group type: COMPARATOR
Intervention: Email-only reminder (no paper reminder)
Number of subjects: 3966
Study 27637296 — intervention group
Group type: EXPERIMENTAL
Intervention: Letters or postcards as reminders
Number of subjects: 3966
Study 21393391 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed disease recognition (symptoms for > 2 years)
Number of subjects: 2967
Study 21393391 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of symptom onset < 36 years
Number of subjects: 2967
Study 21393391 — intervention group
Group type: EXPERIMENTAL
Intervention: History of obstructive airways disease
Number of subjects: 2967
Study 21393391 — intervention group
Group type: EXPERIMENTAL
Intervention: History of sleep apnea
Number of subjects: 2967
Study 21393391 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-minute walk distance < 250 m
Number of subjects: 2967
Study 21393391 — intervention group
Group type: EXPERIMENTAL
Intervention: Right atrial pressure < 10 mm Hg
Number of subjects: 2967
Study 21393391 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vascular resistance < 10 Wood units
Number of subjects: 2967
Study 18499588 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oxygen delivery using 2 EpiFlo oxygen generators providing oxygen at 6 mL/h into an occlusive wound dressing
Number of subjects: 30
Study 18499588 — intervention group
Group type: COMPARATOR
Intervention: Supplemental inspired oxygen (Fio(2) increased from 30% to 50%)
Number of subjects: 30
Study 16814669 — intervention group
Group type: EXPERIMENTAL
Intervention: Acadesine (0.1 mg/kg/min; 7 h intravenous infusion and in cardioplegia solution at 5 microg/ml)
Number of subjects: 2698
Study 16814669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2698
Study 14635629 — intervention group
Group type: EXPERIMENTAL
Intervention: New therapies that are less efficacious but more affordable and feasible than the best current therapeutic standard
Number of subjects: 0
Study 10920152 — intervention group
Group type: EXPERIMENTAL
Intervention: High-threshold surfactant retreatment (FIO(2) >40%, mean airway pressure >7 cm H(2)O)
Number of subjects: 1267
Study 10920152 — intervention group
Group type: COMPARATOR
Intervention: Low-threshold surfactant retreatment (FIO(2) >30%, still requiring endotracheal intubation)
Number of subjects: 1267
Study 10920152 — intervention group
Group type: EXPERIMENTAL
Intervention: High-threshold surfactant retreatment
Number of subjects: 1267
Study 10920152 — intervention group
Group type: COMPARATOR
Intervention: Low-threshold surfactant retreatment
Number of subjects: 1267
Study 8883528 — intervention group
Group type: EXPERIMENTAL
Intervention: iodixanol‐270 (270 mg I/ml)
Number of subjects: 126
Study 8883528 — intervention group
Group type: EXPERIMENTAL
Intervention: iodixanol‐320 (320 mg I/ml)
Number of subjects: 126
Study 8883528 — intervention group
Group type: COMPARATOR
Intervention: iohexol‐300 (300 mg I/ml)
Number of subjects: 126
Study 1578612 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam 4 mg
Number of subjects: 60
Study 1578612 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam 4.5 mg
Number of subjects: 60
Study 1578612 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam 5 mg
Number of subjects: 60
Study 1578612 — intervention group
Group type: EXPERIMENTAL
Intervention: Premedicant determined by body weight
Number of subjects: 60
Study 1578612 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of midazolam
Number of subjects: 60
Study 4006126 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvenous cardioversion
Number of subjects: 15
Study 4006126 — intervention group
Group type: COMPARATOR
Intervention: Rapid ventricular pacing
Number of subjects: 15
Study 29667199 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory stimulation (MSS) for 4 weeks, 3 sessions weekly, 25 minutes each session
Number of subjects: 28
Study 29667199 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 28
Study 30541483 — intervention group
Group type: EXPERIMENTAL
Intervention: FaME exercise programme, 1 hour weekly for 12 weeks, advised to exercise at home for an additional 2 hours
Number of subjects: 64
Study 30541483 — intervention group
Group type: COMPARATOR
Intervention: Usual activities (control group)
Number of subjects: 64
Study 27082062 — intervention group
Group type: EXPERIMENTAL
Intervention: Dovitinib (500 mg/day, 5 days on, 2 days off; n = 82)
Number of subjects: 165
Study 27082062 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib (400 mg twice daily; n = 83)
Number of subjects: 165
Study 27082062 — intervention group
Group type: EXPERIMENTAL
Intervention: Dovitinib
Number of subjects: 165
Study 27082062 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 165
Study 27082062 — intervention group
Group type: EXPERIMENTAL
Intervention: Dovitinib (subgroup analysis)
Number of subjects: 165
Study 23441902 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of topical calcipotriol, NB-UVB, and betamethasone therapies
Number of subjects: 45
Study 23441902 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of NB-UVB and topical calcipotriol
Number of subjects: 45
Study 23441902 — intervention group
Group type: COMPARATOR
Intervention: NB-UVB alone
Number of subjects: 45
Study 22612071 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (200 mg in 100 mL 0.9% saline, as IV infusion 30 minutes before contrast medium administration)
Number of subjects: 60
Study 22612071 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group P)
Number of subjects: 60
Study 20563473 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 19
Study 20563473 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 19
Study 18044544 — intervention group
Group type: EXPERIMENTAL
Intervention: DBP exposure in rats (oral gavage)
Number of subjects: 98
Study 18044544 — intervention group
Group type: EXPERIMENTAL
Intervention: DBP exposure in humans (four men and 94 adults)
Number of subjects: 98
Study 14975457 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 14975457 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 0
Study 14975457 — intervention group
Group type: EXPERIMENTAL
Intervention: COX‐2 inhibitors
Number of subjects: 0
Study 14975457 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with aspirin and other COX inhibitors
Number of subjects: 0
Study 11524482 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-mg Dilantin Kapseals after an 8-hour fast
Number of subjects: 0
Study 11524482 — intervention group
Group type: COMPARATOR
Intervention: 100-mg Dilantin Kapseals after a high-fat meal
Number of subjects: 0
Study 9272803 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose alone (0.05 ml of 24% sucrose placed on the anterior surface of the tongue just prior to heelstick)
Number of subjects: 85
Study 9272803 — intervention group
Group type: COMPARATOR
Intervention: Simulated rocking alone (15 min prior to and during heelstick on an oscillating mattress)
Number of subjects: 85
Study 9272803 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of sucrose and simulated rocking
Number of subjects: 85
Study 9272803 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.05 ml sterile water administered just prior to heelstick)
Number of subjects: 85
Study 7506742 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabexate mesilate, administered within 72 hours of onset of symptoms at a dose of 3 g/24 h
Number of subjects: 0
Study 7506742 — intervention group
Group type: COMPARATOR
Intervention: Aprotinin
Number of subjects: 0
Study 2952161 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas drain left for 6 hours in the peritoneal cavity after laparoscopy.
Number of subjects: 53
Study 2952161 — intervention group
Group type: COMPARATOR
Intervention: Control group (no gas drain).
Number of subjects: 53
Study 29775118 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-flow restricted resistance (BFR) training
Number of subjects: 22
Study 29775118 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising control group
Number of subjects: 22
Study 26983099 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term interactive video games (eight 30-minute sessions) in addition to traditional rehabilitation treatment
Number of subjects: 147
Study 26983099 — intervention group
Group type: COMPARATOR
Intervention: Traditional rehabilitation treatment
Number of subjects: 147
Study 26983099 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term interactive video games
Number of subjects: 147
Study 21883997 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg o.d.
Number of subjects: 27
Study 21883997 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg b.i.d.
Number of subjects: 27
Study 21883997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 19304405 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 61
Study 19304405 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 61
Study 16765526 — intervention group
Group type: EXPERIMENTAL
Intervention: 21‐mg nicotine patch for 3 months, with a 1‐month taper
Number of subjects: 152
Study 16765526 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 152
Study 15957722 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 0
Study 15957722 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 0
Study 12466693 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromelain 300 mg t.i.d.
Number of subjects: 40
Study 12466693 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg t.i.d.
Number of subjects: 40
Study 12466693 — intervention group
Group type: COMPARATOR
Intervention: Placebo t.i.d.
Number of subjects: 40
Study 12466693 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 9523811 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg mivacurium in divided doses (0.15 mg/kg followed by 0.1 mg/kg 30 s later)
Number of subjects: 100
Study 9523811 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 mg/kg rocuronium
Number of subjects: 100
Study 9523811 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 mg/kg rocuronium
Number of subjects: 100
Study 9523811 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg rocuronium
Number of subjects: 100
Study 9523811 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45 mg/kg rocuronium
Number of subjects: 100
Study 9523811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 9523811 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg mivacurium
Number of subjects: 100
Study 8089666 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (52 mg/day for 2.7 years) followed by levodopa (471 mg/day)
Number of subjects: 60
Study 8089666 — intervention group
Group type: COMPARATOR
Intervention: Levodopa alone (569 mg/day)
Number of subjects: 60
Study 8089666 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine followed by levodopa
Number of subjects: 60
Study 2531604 — intervention group
Group type: EXPERIMENTAL
Intervention: hANP (0.7 nmol min‐1)
Number of subjects: 8
Study 31759833 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Goggle
Number of subjects: 139
Study 31759833 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaleidoscope
Number of subjects: 139
Study 31759833 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 139
Study 31221502 — intervention group
Group type: COMPARATOR
Intervention: ACT-541468 25 mg
Number of subjects: 51
Study 31221502 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-541468 25 mg and 75 mg
Number of subjects: 51
Study 31221502 — intervention group
Group type: COMPARATOR
Intervention: ACT-541468 10 mg
Number of subjects: 51
Study 31221502 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-541468 (all doses)
Number of subjects: 51
Study 29324423 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 60
Study 29324423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 25787758 — intervention group
Group type: EXPERIMENTAL
Intervention: Within Our Reach
Number of subjects: 3609
Study 24059602 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced cascaded multiprofessional training program (group A)
Number of subjects: 3681
Study 24059602 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 3681
Study 21865358 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (S)
Number of subjects: 139
Study 21865358 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (M)
Number of subjects: 139
Study 21865358 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin plus Metformin (SM)
Number of subjects: 139
Study 21865358 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (S) and Simvastatin plus Metformin (SM)
Number of subjects: 139
Study 21865358 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (S), Metformin (M), Simvastatin plus Metformin (SM)
Number of subjects: 139
Study 19968005 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained CPAP use (mean use = 13.3 months, SD = 5.2)
Number of subjects: 10
Study 19968005 — intervention group
Group type: COMPARATOR
Intervention: CPAP- (discontinued CPAP)
Number of subjects: 10
Study 17407630 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline ODT 2.5 mg
Number of subjects: 254
Study 17407630 — intervention group
Group type: COMPARATOR
Intervention: Selegiline ODT 1.25 mg
Number of subjects: 254
Study 17407630 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all patients)
Number of subjects: 254
Study 15342804 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen plus breast irradiation
Number of subjects: 769
Study 15342804 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 769
Study 15342804 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen plus breast irradiation (subgroup analysis for T1, receptor-positive tumors)
Number of subjects: 769
Study 15342804 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone (subgroup analysis for T1, receptor-positive tumors)
Number of subjects: 769
Study 15545529 — intervention group
Group type: COMPARATOR
Intervention: Single RF treatment (1 treatment)
Number of subjects: 20
Study 15545529 — intervention group
Group type: EXPERIMENTAL
Intervention: Two RF treatments (2 treatments spaced 1 month apart)
Number of subjects: 20
Study 11059997 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive behavioural family intervention
Number of subjects: 0
Study 11059997 — intervention group
Group type: COMPARATOR
Intervention: Family support programme
Number of subjects: 0
Study 9377992 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone (1 g/100 ml NaCl i.v.)
Number of subjects: 40
Study 9377992 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 ml NaCl i.v.)
Number of subjects: 40
Study 8394864 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine with immune globulin (5 mL)
Number of subjects: 62
Study 8394864 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine alone
Number of subjects: 62
Study 8394864 — intervention group
Group type: COMPARATOR
Intervention: Immune globulin alone
Number of subjects: 62
Study 8394864 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B vaccine
Number of subjects: 62
Study 3732422 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (30 mg/kg, once a week for 6 weeks)
Number of subjects: 12
Study 3732422 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral maintenance corticosteroid therapy (not specified)
Number of subjects: 12
Study 3732422 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 12
Study 29758392 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention (MAP) for 8 weeks
Number of subjects: 40
Study 29758392 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation (PE)
Number of subjects: 40
Study 27788696 — intervention group
Group type: EXPERIMENTAL
Intervention: Mealtime intervention with weekly visits from a trained volunteer who prepared and shared a meal
Number of subjects: 100